RESUMEN
STUDY OBJECTIVES: Hypocretins (HCRT-1 and HCRT-2), also known as orexins, are neuropeptides localized in neurons surrounding the perifornical region of the posterior hypothalamus. These neurons project to major arousal centers in the brain and are implicated in regulating wakefulness. In young rats and monkeys, levels of HCRT-1 are highest at the end of the wake-active period and lowest toward the end of the sleep period. However, the effects of age on the diurnal rhythm of HCRT-1 are not known. DESIGN: To provide such data, cerebrospinal fluid (CSF) was collected from the cisterna magna of young (2-month-old, n = 9), middle-aged (12 months, n = 10), and old (24 months, n = 10) F344 rats at 4-hour intervals, (beginning at zeitgeber [ZT]0, lights on). CSF was collected once from each rat every 4 days at 1 ZT point. After collecting the CSF at all of the time points, the rats were kept awake by gentle handling for 8 hours (ZT 0-ZT8), and the CSF was collected again at the end of the sleep-deprivation procedure. HCRT-1 levels in the CSF were determined by radioimmunoassay SETTINGS: Basic neuroscience research lab. MEASUREMENTS AND RESULTS: Old rats had significantly less HCRT-1 in the CSF versus young and middle-aged rats (P < .002) during the lights-on and lights-off periods and over the 24-hour period. In old rats, significantly low levels of HCRT-1 were evident at the end of the lights-off period (predominantly wake-active period). The old rats continued to have less HCRT-1 even after 8 hours of prolonged waking. Northern blot analysis did not show a difference in pre-proHCRT mRNA between age groups. CONCLUSIONS: In old rats there is a 10% decline in CSF HCRT-1 over the 24-hour period. Functionally, if there is less HCRT-1, which our findings indicated, and there is also a decline in HCRT receptor mRNA, as has been previously found, then the overall consequence would be diminished action of HCRT at target sites. This would diminish the waking drive, which in the elderly could contribute to the increased tendency to fall asleep during the normal wake period.
Asunto(s)
Envejecimiento/fisiología , Proteínas Portadoras/biosíntesis , Ritmo Circadiano/fisiología , Hipotálamo/metabolismo , Péptidos y Proteínas de Señalización Intracelular , Neuropéptidos/biosíntesis , Vigilia/fisiología , Animales , Proteínas Portadoras/líquido cefalorraquídeo , Hipotálamo/anatomía & histología , Neuropéptidos/líquido cefalorraquídeo , Orexinas , ARN Mensajero/análisis , Radioinmunoensayo , Ratas , Ratas Endogámicas F344 , Sueño/fisiologíaAsunto(s)
Proteínas Portadoras/líquido cefalorraquídeo , Trastornos de Somnolencia Excesiva/líquido cefalorraquídeo , Trastornos de Somnolencia Excesiva/patología , Hipotálamo/patología , Hipotálamo/fisiopatología , Péptidos y Proteínas de Señalización Intracelular , Esclerosis Múltiple/complicaciones , Neuropéptidos/líquido cefalorraquídeo , Adulto , Trastornos de Somnolencia Excesiva/etiología , Regulación hacia Abajo/fisiología , Femenino , Humanos , Metilprednisolona/uso terapéutico , Esclerosis Múltiple/patología , Esclerosis Múltiple/fisiopatología , Neuropéptidos/deficiencia , Orexinas , Parasomnias del Sueño REM/líquido cefalorraquídeo , Parasomnias del Sueño REM/etiología , Parasomnias del Sueño REM/patología , Resultado del TratamientoRESUMEN
Rat cisternal (CSF) hypocretin-1 in cerebrospinal fluid was measured after 6 or 96 h of REM sleep deprivation and following 24 h of REM sleep rebound. REM deprivation was found to increase CSF hypocretin-1 collected at zeitgeber time (ZT) 8 but not ZT0. Decreased CSF hypocretin levels were also observed at ZT8 after 24 h of REM sleep rebound. These results suggest that REM sleep deprivation activates and REM sleep rebound inhibits the hypocretin system. Increased hypocretin tone during REM deprivation may be important in mediating some of the effects of REM sleep deprivation such as antidepressant effects, hyperphagia and increased sympathetic activity.
Asunto(s)
Proteínas Portadoras/líquido cefalorraquídeo , Ritmo Circadiano/fisiología , Péptidos y Proteínas de Señalización Intracelular , Neuropéptidos/líquido cefalorraquídeo , Privación de Sueño/líquido cefalorraquídeo , Sueño REM/fisiología , Animales , Hipotálamo/metabolismo , Masculino , Actividad Motora/fisiología , Orexinas , Ratas , Ratas Wistar , Regulación hacia Arriba/fisiología , Vigilia/fisiologíaRESUMEN
The origins of excessive daytime sleepiness in Parkinson disease (PD) are unclear. The authors hypothesize that orexin neurons, a recently identified wake promoting system, could contribute to its pathophysiology. They measured orexin-A/hypocretin-1 concentration in ventricular CSF in 19 parkinsonian patients and compared it with neurologic controls. Orexin levels were lower in patients and decreased with the severity of the disease. The authors suggest that orexin neurons contribute to daytime sleepiness in late stage PD.
Asunto(s)
Trastornos de Somnolencia Excesiva/etiología , Péptidos y Proteínas de Señalización Intracelular , Neuropéptidos/deficiencia , Enfermedad de Parkinson/complicaciones , Antiparkinsonianos/uso terapéutico , Nivel de Alerta/fisiología , Proteínas Portadoras/líquido cefalorraquídeo , Ventrículos Cerebrales , Terapia Combinada , Trastornos de Somnolencia Excesiva/líquido cefalorraquídeo , Terapia por Estimulación Eléctrica , Femenino , Humanos , Masculino , Neuropéptidos/líquido cefalorraquídeo , Orexinas , Enfermedad de Parkinson/líquido cefalorraquídeo , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/terapiaRESUMEN
DESIGN AND PATIENTS: Subjects with Niemann-Pick disease, type C have been reported to display narcolepsylike symptoms, including cataplexy. In this study, 5 patients with juvenile Niemann-Pick disease were evaluted for sleep abnormalities using nocturnal polysomnography, clinical evaluation, and the Multiple Sleep Latency Test. HLA typing and cerebrospinal fluid hypocretin levels were also evaluated in 4 patients. Niemann-Pick disease diagnosis was confirmed in all cases biochemically and by the presence of foam cells in the bone marrow. RESULTS: Deterioration of intellectual function; the presence of pyramidal, dystonic and cerebellar features; and splenomegaly were observed in all cases. Cataplexy was reported in 1 patient. Nocturnal polysomnography revealed disrupted sleep in all patients. Total sleep time, sleep efficiency, rapid eye movement sleep, and delta sleep amounts were decreased when compared to age-matched controls. Altered sleep patterns included sudden increases in muscle tone during delta sleep, electroencephalographic sigma activity connected with rapid eye movements and muscle atonia, atypical K-complexes and spindle activity, and the presence of alpha-delta sleep. All Niemann-Pick disease cases exhibited fragmentary myoclonus. Shortened mean sleep latencies were observed in 3 patients during the Multiple Sleep Latency Test, but sleep-onset rapid eye movement periods were observed only in the case with cataplexy. This patient was HLA DQB1*0602 positive, while the other subjects were HLA negative. Cerebrospinal fluid hypocretin-1 levels were reduced in 2 patients (1 with cataplexy) while in the 2 other patients, the levels were at the lower range of the normal values. Hypocretin levels in the Niemann-Pick disease group (204.8 +/- 39.3 pg/mL) were significantly reduced when compared to controls (265.8 +/- 48.8 pg/mL). CONCLUSIONS: The findings suggest that lysozomal storage abnormalities in Niemann-Pick disease patients may impact the hypothalamus and, more specifically, hypocretin-containing cells. These changes might be partially responsible for sleep abnormalities and cataplexy in patients with Niemann-Pick disease.
Asunto(s)
Péptidos y Proteínas de Señalización Intracelular , Neuropéptidos/deficiencia , Enfermedades de Niemann-Pick/líquido cefalorraquídeo , Enfermedades de Niemann-Pick/complicaciones , Trastornos del Sueño-Vigilia/etiología , Adolescente , Adulto , Proteínas Portadoras/líquido cefalorraquídeo , Femenino , Antígenos HLA-DQ/inmunología , Cadenas beta de HLA-DQ , Humanos , Hipotálamo/metabolismo , Masculino , Neuropéptidos/líquido cefalorraquídeo , Enfermedades de Niemann-Pick/inmunología , Orexinas , Fases del Sueño/fisiología , VigiliaRESUMEN
A case with transient, almost complete sleep loss caused by cerebral manifestation of Whipple's disease (WD) is presented. Cerebral WD is rare and in most cases occurs after gastrointestinal infection. In our case, a progressive and finally almost complete sleep loss was the initial and predominant symptom. Polysomnographic studies in several consecutive nights and over 24 h showed a total abolition of the sleep-wake cycle with nocturnal sleep duration of less than 15 min. Endocrine tests revealed hypothalamic dysfunction with flattening of circadian rhythmicity of cortisol, TSH, growth hormone and melatonin. Cerebrospinal fluid (CSF) hypocretin was reduced. [18F]Deoxyglucose positron emission tomography (FDG-PET) revealed hypermetabolic areas in cortical and subcortical areas including the brainstem, which might explain sleep pathology and vertical gaze palsy. In the course of treatment with antibiotics and additional carbamazepine for 1 year, insomnia slowly and gradually improved. Endocrine investigations at 1-year follow-up showed persistent flattening of circadian rhythmicity. The FDG-PET indicated normalized metabolism in distinct regions of the brain stem which paralleled restoration of sleep length. The extent of sleep disruption in this case of organic insomnia was similar to cases of familial fatal insomnia, but was at least partially reversible with treatment.
Asunto(s)
Encéfalo/fisiopatología , Péptidos y Proteínas de Señalización Intracelular , Privación de Sueño/fisiopatología , Enfermedad de Whipple/fisiopatología , Adulto , Encéfalo/metabolismo , Proteínas Portadoras/líquido cefalorraquídeo , Proteínas Portadoras/metabolismo , Ritmo Circadiano/fisiología , Electroencefalografía , Fijación Ocular/fisiología , Fluorodesoxiglucosa F18 , Estudios de Seguimiento , Humanos , Hidrocortisona/metabolismo , Hipotálamo/metabolismo , Hipotálamo/fisiopatología , Masculino , Melatonina/metabolismo , Neuropéptidos/líquido cefalorraquídeo , Neuropéptidos/metabolismo , Pruebas Neuropsicológicas , Orexinas , Polisomnografía , Radiofármacos , Privación de Sueño/complicaciones , Privación de Sueño/metabolismo , Trastornos del Sueño del Ritmo Circadiano/etiología , Trastornos del Sueño del Ritmo Circadiano/metabolismo , Tirotropina/metabolismo , Tomografía Computarizada de Emisión , Enfermedad de Whipple/metabolismoRESUMEN
Hypocretin (Hcrt or orexin) somas are located in the hypothalamus and project widely to forebrain and brainstem regions, densely innervating monoaminergic and cholinergic cells. Loss of Hcrt function results in the sleep disorder narcolepsy. However, the normal pattern of Hcrt release across the sleep-wake cycle is unknown. We monitored Hcrt-1 release in the basal forebrain, perifornical hypothalamus, and locus ceruleus (LC) across the sleep-wake cycle using microdialysis in freely moving cats and a sensitive solid phase radioimmunoassay. We found that the peptide concentration in dialysates from the hypothalamus was significantly higher during active waking (AW) than during slow-wave sleep (SWS). Moreover, Hcrt-1 release was significantly higher during rapid eye movement (REM) sleep than during SWS in the hypothalamus and basal forebrain. We did not detect a significant difference in release across sleep-waking states in the LC, perhaps because recovered levels of the peptide were lower at this site. Because there was a trend toward higher levels of Hcrt-1 release during AW compared with quiet waking (QW) in our 10 min dialysis samples, we compared Hcrt-1 levels in CSF in 2 hr AW and QW periods. Hcrt-1 release into CSF was 67% higher during AW than during QW. Elevated levels of Hcrt during REM sleep and AW are consistent with a role for Hcrt in the central programming of motor activity.
Asunto(s)
Encéfalo/metabolismo , Proteínas Portadoras/metabolismo , Péptidos y Proteínas de Señalización Intracelular , Neuropéptidos/metabolismo , Sueño , Vigilia , Animales , Proteínas Portadoras/líquido cefalorraquídeo , Proteínas Portadoras/inmunología , Gatos , Femenino , Hipotálamo/metabolismo , Cinética , Locus Coeruleus/metabolismo , Masculino , Neuropéptidos/líquido cefalorraquídeo , Neuropéptidos/inmunología , Orexinas , Periodicidad , Prosencéfalo/metabolismo , RadioinmunoensayoRESUMEN
Orexin, a hypothalamic neuropeptide, has been revealed to be involved in sleep regulation. To elucidate functions of orexin in brainstem sleep regulation mechanism, we examined the effects of orexin applied from micropipettes with air pressure on neurones in and around the laterodorsal tegmental nucleus (LDT). In five of seven cholinergic neurones and six of nine non-cholinergic neurones orexin induced long-lasting excitation. These results suggest that hypothalamic orexin neurones may affect the LDT neurones directly, and thereby participate in control of sleep.